1985
DOI: 10.1016/0006-2952(85)90291-6
|View full text |Cite
|
Sign up to set email alerts
|

Influence of ionic strength on the binding of sodium aurothiosulphate to human serum albumin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

1986
1986
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 13 publications
0
2
0
Order By: Relevance
“…The binding mechanism suggested in the present study agrees with that suggested for the binding of aurothiosulphate to human albumin. '9 20 Although aurothiomalate and aurothiosulphate are respectively organic and inorganic compounds, the similar values for the association contants of the two compounds also support the hypothesis that the same binding mechanism applies. Assuming n=4 identical values of K, are obtained, suggesting that it is the sulphydryl group (SH) of Cys(34) which is the high affinity binding site.…”
Section: Discussionmentioning
confidence: 68%
“…The binding mechanism suggested in the present study agrees with that suggested for the binding of aurothiosulphate to human albumin. '9 20 Although aurothiomalate and aurothiosulphate are respectively organic and inorganic compounds, the similar values for the association contants of the two compounds also support the hypothesis that the same binding mechanism applies. Assuming n=4 identical values of K, are obtained, suggesting that it is the sulphydryl group (SH) of Cys(34) which is the high affinity binding site.…”
Section: Discussionmentioning
confidence: 68%
“…Herein, we proposed a competitive ABPP strategy (Figure B), including identification experiments and reactivity classification experiments for the target profiles in proteomes of four Au­(I) complexes: Auranofin (AF), Aurothioglucose (ATG), Aurothiomalate (ATM), and Aaurothiosulfate (ATS) (Figure A). Of these Au­(I) complexes, AF has been approved by the US Food and Drug Administration for Phase II clinical trial to treat cancer .…”
mentioning
confidence: 99%